Areewan Cheawchanwattana

Dr. Areewan Cheawchanwattana


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 February 2019 in Health and Quality of Life Outcomes
Verified
Journal Article
Open access
PDF file
PCPattariya Chantarasap
Pattariya Chantarasap
NJNutjaree Pratheepawanit Johns
Nutjaree Pratheepawanit Johns
SPSrivieng Pairojkul
Srivieng Pairojkul
ASAumkhae Sookprasert
Aumkhae Sookprasert
KWKosin Wirasorn
Kosin Wirasorn
SSSuphat Subongkot
Suphat Subongkot
Cancer not only impairs a patient’s physical and psychosocial functional behaviour, but also contributes to negative impact on family members’ health related quality of life. Currently, there is an absence of a relevant tool in Thai with which to measure such impact. The aim of this study was to translate and validate the Family Reported Outcome Measure (FROM-16) in Thai cancer patients’ family members. Thai version of FROM-16 was generated by interactive forward-backward translation process following standard guidelines. This was tested for psychometric properties including reliability and validity, namely content validity, concurrent validity, known group validity, internal consistency, exploratory and confirmatory factor analysis. Construct validity was examined by comparing the Thai FROM-16 version with the WHOQOL-BREF-THAI. The internal consistency reliability was strong (Cronbach’s alpha = 0.86). A Negative moderate correlation between the Thai FROM-16 and WHOQOL-BREF-THAI was observed (r = − 0.4545, p < 0.00), and known group validity was proved by a statistically significant higher score in family members with high burden of care and insufficient income. The factor analysis supported both 3-factor and 2-factor loading model with slight difference when compared with the original version. The Thai FROM-16 showed good reliability and validity in Thai family members of patients with cancer. A slight difference in factor analysis results compared to the original version could be due to cross-culture application.

22 October 2015 in Religions
Verified
Journal Article
Open access
PDF file
WSWaraporn Saisunantararom
Waraporn Saisunantararom
ACAreewan Cheawchanwattana
Areewan Cheawchanwattana
TKTALERNGSAK KANJANABUCH
TALERNGSAK KANJANABUCH
MBMaliwan Buranapatana
Maliwan Buranapatana
KCKornkaew Chanthapasa
Kornkaew Chanthapasa
There are numerous studies of quality of life (QOL) in chronic kidney disease (CKD) patients; however, there are a few studies of spirituality and its association with QOL. Previous studies were done focusing on Western cultures; thus, the study of CKD patients in Eastern cultures would reveal interesting insights. This study was conducted to explore the spirituality, QOL, and depression of Thai CKD patients, and the associations between spirituality, QOL, and depression. This cross-sectional descriptive study using structured questionnaires was approved by the Khon Kaen University Ethics Committee in Human Research, Thailand. A total of 63 pre-dialysis CKD stage V patients who visited the kidney diseases clinic as appointed at the outpatient department in a community hospital in northeastern Thailand were recruited. The patients were asked for consent and then interviewed. Spirituality was assessed by using the WHOQOL Spirituality, Religiousness and Personal Beliefs (WHOQOL-SRPB) and the Functional Assessment of Chronic Illness Therapy-Spiritual Well-Being Scale (FACIT-Sp). The 9-item Thai Health Status Assessment Instrument (9-THAI) was used to assess QOL. The Beck Depression Inventory-II (BDI-II) was used to evaluate the depression. The study patients had high WHOQOL-SRPB and FACIT-Sp spirituality scores (median = 18.0, and 44.0, respectively). The 9-THAI QOL scores were within the normal range of the Thai general, healthy population (physical health score [PHS]; median = 48.0, mental health score [MHS]; median = 32.0). Based on BDI-II scores, most patients were in the minimal depression group (63.5%). The Spearman rho correlation coefficients (rs) of PHS and WHOQOL-SRPB and FACIT-Sp were moderate with 0.34 for both spirituality measures. Similarly, also the mental health scores (MHS) correlated moderately with WHOQOL-SRPB (rs = 0.46) and FACIT-Sp (rs = 0.37). Depressive symptoms (BDI-II) strongly negatively correlated with WHOQOL-SRPB (rs = −0.58) and FACIT-Sp (rs = −0.55). Overall results were consistent with previous studies in Western contexts. Understanding spirituality would lead to the better management of depression and improving patient survival. These significant associations suggest that further research is needed on how provider knowledge of patient spirituality could affect the outcomes for patients both in terms of depression and patient survival.

29 December 2014 in Religions
Verified
Journal Article
Open access
PDF file
ACAreewan Cheawchanwattana
Areewan Cheawchanwattana
DCDarunee Chunlertrith
Darunee Chunlertrith
WSWaraporn Saisunantararom
Waraporn Saisunantararom
NJNutjaree Pratheepawanit Johns
Nutjaree Pratheepawanit Johns
Spiritual well-being is viewed as an essential component of health-related quality of life (HRQOL) in the modernized biopsychosocial-spiritual model of health. Understanding spiritual well-being should lead to better treatment plans from the patients’ point of view, and improved patient adherence. There are numerous studies of traditional HRQOL, physical, mental, and social well-being; however, studies of spiritual well-being in chronic kidney disease (CKD) patients are limited. Thus, this study compared spiritual well-being of chronic hemodialysis patients and pre-dialysis CKD patients. A total of 31 chronic hemodialysis and 63 pre-dialysis CKD patients were asked for consent and then interviewed for spiritual well-being using the Functional Assessment of Chronic Illness Therapy–Spiritual Well-Being (FACIT-Sp). Analysis of covariance was applied to compare FACIT-Sp scores between pre-dialysis CKD and chronic hemodialysis groups that were adjusted by patient characteristics. The FACIT-Sp scores of pre-dialysis CKD patients were non-significantly greater than those of chronic hemodialysis patients after adjustment for gender, age, and marital status. However, all FACIT-Sp scores of males were significantly lower than those of females [FACIT Meaning −1.59 (p = 0.024), FACIT Peace −2.37 (p = 0.004), FACIT Faith −2.87 (p = 0.001), FACIT Total Score −6.83 (p = 0.001)]. The spiritual well-being did not significantly differ by stages of chronic kidney disease; however, patient gender was associated with spiritual well-being instead. To improve spiritual well-being, researchers should consider patient gender as a significant factor.

25 May 2019 in Nutrients
Verified
Journal Article
Open access
PDF file
BSBungorn Sripanidkulchai
Bungorn Sripanidkulchai
CMCatheleeya Mekjaruskul
Catheleeya Mekjaruskul
RARosawan Areemit
Rosawan Areemit
ACAreewan Cheawchanwattana
Areewan Cheawchanwattana
JSJiraporn Sithithaworn
Jiraporn Sithithaworn
Kaempferia parviflora Wall. ex Baker (KP), Krachaidam in Thai or Thai ginseng, is a herbal medicine that has many potential pharmacological effects. The effect of KP extract on blood glucose level in rodent was reported. This study focused on the oral glucose tolerance test and pharmacokinetic study in healthy volunteers administered with KP extract (90 and 180 mg/day, placebo). The oral glucose tolerance tests were performed at baselines and 28-days of administration. The pharmacokinetics were determined after a single dose administration of the tested products using 3,5,7,3′,4′-pentamethoxyflavone (PMF) and 5,7,4′-trimethoxylflavone (TMF) as markers. The results showed that glucose metabolism via oral glucose tolerance test was not affected by KP extract. Blood glucose levels of volunteers at 120 min after glucose loading were able to be returned to initial levels in placebo, KP 90 mg/day, and KP 180 mg/day groups both at baseline and 28-days of administration. The results of the pharmacokinetic study revealed that only TMF and PMF, but not 5,7-dimethoxyflavone (DMF) levels could be detected in human blood. The given doses of KP extract at 90 and 180 mg/day showed a linear dose-relationship of blood PMF concentration whereas blood TMF was detected only at high given dose (180 mg/day). The half-lives of PMF and TMF were 2–3 h. The maximum concentration (Cmax), area under the curve of blood concentration and time (AUC), and time to maximum concentration (Tmax) values of PMF and TMF estimated for the 180 mg/day dose were 71.2 ± 11.3, 63.0 ± 18.0 ng/mL; 291.9 ± 48.2, 412.2 ± 203.7 ng∙h/mL; and 4.02 ± 0.37, 6.03 ± 0.96 h, respectively. PMF was quickly eliminated with higher Ke and Cl than TMF at the dose of 180 mg/day of KP extract. In conclusion, the results demonstrated that KP extract had no effect on the glucose tolerance test. In addition, this is the first demonstration of the pharmacokinetic parameters of methoxyflavones of KP extract in healthy volunteers. The data suggest the safety of the KP extract and will be of benefit for further clinical trials using KP extract as food and sport supplements as well as a drug in health product development.

22 April 2019 in Preprints.org
Verified
Preprint
Open access
PDF file
BSBungorn Sripanidkulchai
Bungorn Sripanidkulchai
CMCatheleeya Mekjaruskul
Catheleeya Mekjaruskul
RARosawan Areemit
Rosawan Areemit
ACAreewan Cheawchanwattana
Areewan Cheawchanwattana
JSJiraporn Sithithaworn
Jiraporn Sithithaworn
Kaempferia parviflora Wall. ex Baker (KP), Krachaidam in Thai or Thai ginseng, is an herbal medicine that has many potential pharmacological effects. This study focused on the oral glucose tolerance test and pharmacokinetic study in healthy volunteers administered with KP extract (90 and 180 mg/day, placebo). The oral glucose tolerance tests were performed at baselines and 28-days of administration. The pharmacokinetics were determined after a single dose administration of the tested products using 3,5,7,3,4-pentamethoxyflavone (PMF) and 5,7,4-trimethoxylfavone (TMF) as markers. The results showed that glucose metabolism via oral glucose tolerance test was not affected by KP extract. The results of pharmacokinetics study revealed that only TMF and PMF, but not DMF levels could be detected in human blood. The given doses of KP extract at 90 and 180 mg/day showed a linear dose-relationship of blood PMF concentration whereas blood TMF was detected only at high given dose (180 mg/day). The half-lives of PMF and TMF were 2–3 h. The Cmax, AUC and Tmax values of PMF and TMF estimated for the 180 mg/day dose were 85.3711.31, 73.2329.93 mg/ml; 291.8948.23, 412.20203.69 mg.h/ml; and 3.890.37, 4.500.96 h, respectively. PMF was quickly eliminated with higher Ke and Cl than TMF at the dose of 180 mg/day of KP extract. In conclusion, the results demonstrated that KP extract had no effect on glucose tolerance test. In addition, this is the first demonstration of the pharmacokinetic parameters of methoxyflavones of KP extract in healthy volunteers in a phase I study in drug development. The data suggest the safety of the KP extract and will be of benefit for further clinical trials using KP extract as food and sport supplements as well as a drug in health product development.